Dompé: The First International Clinical Ophthalmological Trial Concerning Treatment of Neurotrophic Keratitis (NK), an Ocular Pathology With No Cure, Takes Place in Italy

MILANO--(BUSINESS WIRE)--Dompé, one of the leading biopharmaceutical companies in Italy, announced today that it has initiated a Phase I clinical trial on the use of recombinant human Nerve Growth Factor (rhNGF), the discovery of which earned Professor Rita Levi Montalcini a Nobel Prize, for treating neurotrophic keratitis, a rare ocular pathology which still has no cure, and affects one person in 10,000 worldwide.